Covid 19 medicine in India: Gilead Sciences ties up with Noida-based Jubilant to sell remdesivir
Covid 19 medicine in India: Noida-based Jubilant Life Sciences on Tuesday announced that its subsidiary Jubilant Generics Ltd has entered into a non-exclusive licensing agreement with US-based Gilead Sciences to manufacture and sell anti-viral drug remdesivir, which is under clinical trials globally as a potential treatment of COVID-19 disease
The pact allows Jubilant to register, manufacture and sell remdesivir in 127 countries, including in India. Source: Website